Cardiologists are facing a shortage of the thrombolytic agent tenecteplase (Metalyse) because limited supplies are being used inappropriately in place of alteplase for the treatment of acute stroke. Tenecteplase is being adopted with enthusiasm for the treatment of stroke because of its more convenient single bolus dosing compared to the infusion needed for alteplase, according ...
Thrombolytic shortage looms due to inappropriate use in stroke patients
By Michael Woodhead
6 Aug 2020